used with or in lieu of vinca alkaloids as well, and in different indications, and Veru would seek these indication expansions in time. Xtandi and Zytiga both have multibillion dollar markets. We believe that VERU-111 could easily achieve indication expansion and can be used in other indications and

s even more important since the established second line androgen-targeting drugs in use for Prostate cancer, the likes of Xtandi (enzalutamide) and Zytiga (abiraterone/prednisone) have a very high degree of cross resistance and cannot be used in sequence for a long-term management strategy for Prostat